CY1107519T1 - Yποκατεστημενες χαλκονες ως θepαπευτικες ενωσεις - Google Patents
Yποκατεστημενες χαλκονες ως θepαπευτικες ενωσειςInfo
- Publication number
- CY1107519T1 CY1107519T1 CY20061101338T CY061101338T CY1107519T1 CY 1107519 T1 CY1107519 T1 CY 1107519T1 CY 20061101338 T CY20061101338 T CY 20061101338T CY 061101338 T CY061101338 T CY 061101338T CY 1107519 T1 CY1107519 T1 CY 1107519T1
- Authority
- CY
- Cyprus
- Prior art keywords
- group
- substituted
- 4alkyl
- therapeutic
- balkons
- Prior art date
Links
- 230000001225 therapeutic effect Effects 0.000 title abstract 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 1
- WUXJXFIZNJPAMA-UHFFFAOYSA-N 1-(3,5-dimethoxyphenyl)-3-(4-methoxyphenyl)prop-2-en-1-one Chemical class C1=CC(OC)=CC=C1C=CC(=O)C1=CC(OC)=CC(OC)=C1 WUXJXFIZNJPAMA-UHFFFAOYSA-N 0.000 abstract 1
- DQFBYFPFKXHELB-UHFFFAOYSA-N Chalcone Natural products C=1C=CC=CC=1C(=O)C=CC1=CC=CC=C1 DQFBYFPFKXHELB-UHFFFAOYSA-N 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 229940121363 anti-inflammatory agent Drugs 0.000 abstract 1
- 239000002260 anti-inflammatory agent Substances 0.000 abstract 1
- 230000001028 anti-proliverative effect Effects 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 150000001789 chalcones Chemical class 0.000 abstract 1
- 235000005513 chalcones Nutrition 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 238000003745 diagnosis Methods 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 230000004968 inflammatory condition Effects 0.000 abstract 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000003389 potentiating effect Effects 0.000 abstract 1
- 230000002062 proliferating effect Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/15—Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C251/00—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton
- C07C251/32—Oximes
- C07C251/34—Oximes with oxygen atoms of oxyimino groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
- C07C251/36—Oximes with oxygen atoms of oxyimino groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with the carbon atoms of the oxyimino groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C251/40—Oximes with oxygen atoms of oxyimino groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with the carbon atoms of the oxyimino groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of an unsaturated carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C305/00—Esters of sulfuric acids
- C07C305/22—Esters of sulfuric acids having oxygen atoms of sulfate groups bound to carbon atoms of six-membered aromatic rings
- C07C305/24—Esters of sulfuric acids having oxygen atoms of sulfate groups bound to carbon atoms of six-membered aromatic rings of non-condensed six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/017—Esters of hydroxy compounds having the esterified hydroxy group bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
- C07F9/12—Esters of phosphoric acids with hydroxyaryl compounds
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/902—Oxidoreductases (1.)
- G01N2333/90209—Oxidoreductases (1.) acting on NADH or NADPH (1.6), e.g. those with a heme protein as acceptor (1.6.2) (general), Cytochrome-b5 reductase (1.6.2.2) or NADPH-cytochrome P450 reductase (1.6.2.4)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Rheumatology (AREA)
- Cell Biology (AREA)
- Oncology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Pulmonology (AREA)
- Microbiology (AREA)
- Emergency Medicine (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Η εφεύρεση αυτή αναφέρεται σε υποκατεστημένες χαλκόνες, ειδικά υποκατεστημένες 1-(4-μεθοξυφαινυλο)-3-(3,5-διμεθοξυφαινυλο)προπ-1-εν-3-όνες, οι οποίες έχουν θεραπευτική εφαρμογή, για παράδειγμα, ως ισχυροί αντιπολλαπλασιαστικοί παράγοντες και αντιφλεγμονώδεις παράγοντες, και οι οποίες έχουν τον τύπο (I) όπου: το Χ είναι -Η, -OH, -OC(=O)R3, -OS(=O)2OH, ή -ΟΡ(=O)2(ΟΗ)2˙ το Υ είναι -Η ή μια C1-4 αλκυλική ομάδα˙ το Ζ είναι -Η ή -OCH3˙ το R1 είναι -Η, μια C1-4 αλκυλική ομάδα ή μια C1-4 φθοραλκυλική ομάδα˙ το R2 είναι -Η, μια C1-4 αλκυλική ομάδα ή μια C1-4 φθοραλκυλική ομάδα˙ και το R3 είναι -Η, μια C1-6 αλκυλική ομάδα, μια C3-20ετεροκυκλική ομάδα, ή μια C5-20 αρυλική ομάδα˙ και φαρμακευτικώς αποδεκτά άλατα, εστέρες, και προστατευμένες μορφές αυτών. Η παρούσα εφεύρεση επίσης αναφέρεται σε φαρμακευτικές συνθέσεις οι οποίες περιλαμβάνουν τέτοιες ενώσεις, και τη χρήση αυτών των ενώσεων και των συνθέσεων, τόσο in vitro όσο και in vivo, για αμφότερες διάγνωση και αντιμετώπιση, για παράδειγμα, πολλαπλασιαστικών καταστάσεων, όπως ο καρκίνος, και φλεγμονωδών καταστάσεων.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0007401.3A GB0007401D0 (en) | 2000-03-27 | 2000-03-27 | Substituted chalcones as therapeeutic compounds |
EP01914064A EP1284952B1 (en) | 2000-03-27 | 2001-03-26 | Substituted chalcones as therapeutic compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1107519T1 true CY1107519T1 (el) | 2013-03-13 |
Family
ID=9888505
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20061101338T CY1107519T1 (el) | 2000-03-27 | 2006-09-20 | Yποκατεστημενες χαλκονες ως θepαπευτικες ενωσεις |
Country Status (14)
Country | Link |
---|---|
US (1) | US6787672B2 (el) |
EP (1) | EP1284952B1 (el) |
JP (1) | JP5235257B2 (el) |
AT (1) | ATE330928T1 (el) |
AU (1) | AU784609B2 (el) |
CA (1) | CA2403900C (el) |
CY (1) | CY1107519T1 (el) |
DE (1) | DE60120962T2 (el) |
DK (1) | DK1284952T3 (el) |
ES (1) | ES2269360T3 (el) |
GB (1) | GB0007401D0 (el) |
NZ (1) | NZ521595A (el) |
PT (1) | PT1284952E (el) |
WO (1) | WO2001072680A1 (el) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0123777D0 (en) | 2001-10-03 | 2001-11-21 | Cancer Res Ventures Ltd | Substituted chalcones as therapeutic agents |
GB0123780D0 (en) * | 2001-10-03 | 2001-11-21 | Cancer Res Ventures Ltd | Substituted chalcones as therapeutic agents |
RU2004121898A (ru) * | 2001-12-19 | 2006-01-20 | Атеродженикс, Инк. (Us) | Производные халкона и их применение для лечения заболеваний |
WO2005115992A1 (en) * | 2004-05-23 | 2005-12-08 | Housey Pharmaceuticals, Inc. | Theramutein modulators |
KR100597871B1 (ko) * | 2004-06-08 | 2006-07-06 | 학교법인 영남학원 | 방향환을 함유하는 신규 프로페논 유도체 및 이를 함유하는 항염증제 |
DE102006018988B3 (de) * | 2006-04-25 | 2007-08-09 | Nateco2 Gmbh & Co. Kg | Verfahren zur Herstellung eines Xanthohumol-haltigen Pulvers hoher Reinheit und dessen Verwendung |
US7714025B2 (en) | 2006-05-10 | 2010-05-11 | Arizona Biomedical Research Commission | Modified chalcone compounds as antimitotic agents |
SI2219451T1 (sl) | 2007-11-21 | 2015-02-27 | Oxigene, Inc. | Postopek za zdravljenje hematopoetskih neoplazem |
GB0907551D0 (en) | 2009-05-01 | 2009-06-10 | Univ Dundee | Treatment or prophylaxis of proliferative conditions |
WO2011009826A2 (en) | 2009-07-21 | 2011-01-27 | ADAMED Sp.z o.o. | Novel chalcone derivatives with cytotoxic activity |
CN102397269B (zh) * | 2011-09-20 | 2015-01-07 | 温州医学院 | 查尔酮类化合物在制备抗炎药物中的应用 |
KR101333735B1 (ko) * | 2011-11-01 | 2013-11-27 | 건국대학교 산학협력단 | 디페닐프로페논 화합물를 유효성분으로 포함하는 신경계 염증질환 예방 및 치료용 약학조성물 |
CN103102283B (zh) * | 2011-11-09 | 2014-05-28 | 南京大学 | 一种查耳酮肟类化合物作为新型免疫抑制剂的制备方法与用途 |
CN103664689A (zh) * | 2013-11-04 | 2014-03-26 | 南京大学 | 对癌细胞微管蛋白聚合有抑制作用的一类查尔酮肟衍生物及其制备方法 |
KR101558500B1 (ko) * | 2014-02-26 | 2015-10-12 | 건국대학교 산학협력단 | 신규한 메톡시칼콘 유도체 및 그 항암제로의 용도 |
US11419934B2 (en) | 2015-08-18 | 2022-08-23 | Oncotelic Therapeutics, Inc. | Use of VDAS to enhance immunomodulating therapies against tumors |
PE20210367A1 (es) | 2018-02-02 | 2021-02-26 | Maverix Oncology Inc | Conjugados de farmacos de molecula pequena de monofosfato de gemcitabina |
CN115850048B (zh) * | 2022-12-01 | 2024-05-10 | 东南大学 | 一种合成2芳基丁烯酮类化合物的方法 |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4279930A (en) * | 1978-10-10 | 1981-07-21 | The Upjohn Company | Process for treating inflammation |
JPS60237039A (ja) * | 1984-05-08 | 1985-11-25 | Nippon Oil & Fats Co Ltd | ベンザルアセトフエノン及びその誘導体の製造方法 |
JPS6176433A (ja) | 1984-09-21 | 1986-04-18 | Toyobo Co Ltd | 新規なカルコン誘導体 |
LU86715A1 (fr) | 1986-12-16 | 1988-07-14 | Oreal | Composition cosmetique contenant des derives hydroxyles de chalcone et son utilisation pour la protection de la peau et des cheveux contre les radiations lumineuses,nouveaux derives hydroxyles de chalcone utilises et leur procede de preparation |
JPH02142717A (ja) | 1988-11-22 | 1990-05-31 | Kanebo Ltd | 養毛化粧料 |
JPH05246932A (ja) | 1992-03-04 | 1993-09-24 | Nippon High Potsukusu:Kk | 3,4−ジヒドロキシカルコン誘導体 |
US5430062A (en) * | 1992-05-21 | 1995-07-04 | Research Corporation Technologies, Inc. | Stilbene derivatives as anticancer agents |
KR960703901A (ko) | 1993-08-19 | 1996-08-31 | 로즈 암스트롱 | 치환된 2(5H)푸라논, 2(5H)티오페논 및 2(5H)피롤론 유도체, 그의 제조 방법 및 엔도텔린 길항제로서의 그의 용도(Substituted 2(5H)Furanone, 2(5H)Thiophenone and 2(5H)Pyrrolone Derivatives, Their Preparation and Their Use as Endothelin antagonists) |
JPH08188546A (ja) | 1995-01-04 | 1996-07-23 | Kyowa Hakko Kogyo Co Ltd | カルコン誘導体 |
GB9519490D0 (en) | 1995-09-25 | 1995-11-29 | Melvin William T | Use of a cytochrome P450 enzyme in tumour cells as a marker and target |
WO1999000114A2 (en) | 1997-06-26 | 1999-01-07 | Statens Serum Institut | Biologically active 1,3-bis-aromatic-prop-2-en-1-ones, 1,3-bis-aromatic-propan-1-ones, and 1,3-bis-aromatic-prop-2-yn-1-ones |
CA2319836C (en) | 1998-02-06 | 2010-11-23 | De Montfort University | Hydroxylation activated prodrugs |
GB9802522D0 (en) | 1998-02-06 | 1998-04-01 | Montford University De | Hydroxylation activated prodrugs |
AU2291001A (en) | 1999-12-23 | 2001-07-03 | Emory University | Chalcone and its analogs as agents for the inhibition of angiogenesis and related disease states |
-
2000
- 2000-03-27 GB GBGB0007401.3A patent/GB0007401D0/en not_active Ceased
-
2001
- 2001-03-26 NZ NZ521595A patent/NZ521595A/en not_active IP Right Cessation
- 2001-03-26 CA CA2403900A patent/CA2403900C/en not_active Expired - Fee Related
- 2001-03-26 ES ES01914064T patent/ES2269360T3/es not_active Expired - Lifetime
- 2001-03-26 PT PT01914064T patent/PT1284952E/pt unknown
- 2001-03-26 JP JP2001570595A patent/JP5235257B2/ja not_active Expired - Fee Related
- 2001-03-26 DK DK01914064T patent/DK1284952T3/da active
- 2001-03-26 DE DE60120962T patent/DE60120962T2/de not_active Expired - Lifetime
- 2001-03-26 AU AU39450/01A patent/AU784609B2/en not_active Ceased
- 2001-03-26 US US10/239,757 patent/US6787672B2/en not_active Expired - Fee Related
- 2001-03-26 AT AT01914064T patent/ATE330928T1/de active
- 2001-03-26 EP EP01914064A patent/EP1284952B1/en not_active Expired - Lifetime
- 2001-03-26 WO PCT/GB2001/001341 patent/WO2001072680A1/en active IP Right Grant
-
2006
- 2006-09-20 CY CY20061101338T patent/CY1107519T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
GB0007401D0 (en) | 2000-05-17 |
AU3945001A (en) | 2001-10-08 |
EP1284952B1 (en) | 2006-06-21 |
DE60120962T2 (de) | 2007-02-08 |
US6787672B2 (en) | 2004-09-07 |
CA2403900A1 (en) | 2001-10-04 |
JP5235257B2 (ja) | 2013-07-10 |
US20030100538A1 (en) | 2003-05-29 |
ATE330928T1 (de) | 2006-07-15 |
DE60120962D1 (de) | 2006-08-03 |
ES2269360T3 (es) | 2007-04-01 |
PT1284952E (pt) | 2006-11-30 |
CA2403900C (en) | 2011-02-08 |
NZ521595A (en) | 2005-04-29 |
AU784609B2 (en) | 2006-05-11 |
DK1284952T3 (da) | 2006-10-30 |
WO2001072680A1 (en) | 2001-10-04 |
EP1284952A1 (en) | 2003-02-26 |
JP2003528842A (ja) | 2003-09-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1107519T1 (el) | Yποκατεστημενες χαλκονες ως θepαπευτικες ενωσεις | |
AP1422A (en) | 6.Alpha.,9.alpha.-difluoro-17.alpha.-'(2-furanylcarboxyl)oxy!-11.beta.-hydroxy-16.alpha.-methyl-3-oxo-androst-1,4,-diene-17-carbothioic acid s-fluoromethyl ester as an anti-inflammatory agent. | |
ID27178A (id) | Senyawa aminosikloheksil eter dan penggunaannya | |
ATE440603T1 (de) | 8-hydroxychinolinderivate | |
TR200200706T2 (tr) | Nöropatik ağrı tedavisi için retigabin kullanımı. | |
EA200300788A1 (ru) | Производные замещенных алкиламинов и их применение | |
WO2001064642A3 (en) | Benzamides and related inhibitors of factor xa | |
SE0101932D0 (sv) | Pharmaceutical combinations | |
YU87202A (sh) | Derivati arilmetilamina koji se koriste kao inhibitori triptaze | |
BR0005616A (pt) | 2-(3,5-bis-trifluormetil-fenil)-n-metil-n-(6-morfolin-4-i l-4-o-tolil-piridin-3-il)-isobutiramida | |
DK1228758T3 (da) | Anvendelse af sulfodehydroabietinsyre til behandling af inflammatorisk tarmsygdom | |
SE0003476D0 (sv) | Compounds | |
EA200100906A1 (ru) | Композиция контролируемого высвобождения для лечения copd хронического обструктивного заболевания легких | |
ATE308540T1 (de) | Antithrombosemittel | |
WO2003028713A3 (en) | 3,4-methylenedioxy-substituted chalcones as therapeutic agents | |
SE0004827D0 (sv) | Therapeutic compounds | |
NO20032407L (no) | Anvendelse av 6-dimetylaminometyl-1-fenyl- cykloheksanforbindelser for behandling av urininkontinens | |
ES2284970T3 (es) | Compuestos amina 1,2- y 1,3-diol y su utilizacion para el tratamiento de alzheimer. | |
TNSN03077A1 (en) | Quinoline derivatives and their use as antibiotics |